炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第2笔成交价格为16.30元，成交12.30万股，成交金额200.49万元，溢价率为-8.43%，买方营业部为招商 证券股份有限公司北京分公司，卖方营业部为民生证券股份有限公司济南千佛山路证券营业部。 1月7日，力诺药包收涨0.45%，收盘价为17.80元，发生3笔大宗交易，合计成交量36.9万股，成交金额 601.47万元。 第1笔成交价格为16.30元，成交12.30万股，成交金额200.49万元，溢价率为-8.43%，买方营业部为东方 财富证券股份有限公司拉萨团结路第一证券营业部，卖方营业部为民生证券股份有限公司济南千佛山路 证券营业部。 第3笔成交价格为16.30元，成交12.30万股，成交金额200.49万元，溢价率为-8.43%，买方营业部为华泰 证券股份有限公司广东分公司，卖方营业部为民生证券股份有限公司济南千佛山路证券营业部。 进一步统计，近3个月内该股累计发生6笔大宗交易，合计成交金额为1214.35万元。该股近5个交易日累 计下跌0.06%，主力资金合计净流出1240.04万元。 责任编辑：小浪快报 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 2025 年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、力诺转债（债券代码：123221）转股期限为 2024 年 2 月 29 日至 2029 年 8 月 22 日，最新转股价格为 14.20 元/股。 2、2025 年第四季度，共有 0 张"力诺转债"转股，共计转换成"力诺药 包"股票 0 股。 3、截至 2025 年第四季度末，公司剩余可转换公司债券为 4,053,297 张， 剩余票面总金额为人民币 405,329,700 元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上 市公司自律监管指引第 15 号——可转换公司债券》的有关规定，山东力诺 医药包装股份有限公司（以下简称"公司"）现将 2025 年第四季度可转换 公司债券（以下简称"可转债"） 转股及公司总 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance and financial metrics, with a notable increase in stock price year-to-date, but a decline in revenue and net profit for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22% [2]. - The net profit attributable to shareholders for the same period was 50.88 million yuan, reflecting a year-on-year decline of 27.80% [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [3]. Stock Market Activity - On December 29, Linuo Pharmaceutical's stock rose by 2.11%, reaching 17.90 yuan per share, with a trading volume of 58.95 million yuan and a turnover rate of 1.40% [1]. - The company's market capitalization stands at 4.279 billion yuan [1]. - Year-to-date, the stock price has increased by 19.95%, with a 1.94% rise over the last five trading days, 5.05% over the last 20 days, and 3.71% over the last 60 days [1]. Shareholder Composition - The number of shareholders increased to 17,600 as of September 30, 2025, marking a 58.60% rise from the previous period [2]. - The average number of tradable shares per shareholder decreased by 36.94% to 13,571 shares [2]. - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed Fund and Green High Dividend Preferred Mixed Fund, among others [3].

Core Viewpoint - The management of Lino Pharmaceutical has explained the recent adjustments in leadership, performance fluctuations, and shareholder reductions, emphasizing the company's commitment to long-term development and strategic transformation [1][2]. Group 1: Management Adjustments - The management changes at Lino Pharmaceutical occurred mainly in October and December, including the resignation of the former chairman and other board members, with a focus on optimizing governance and enhancing organizational vitality [1][2]. - The adjustments are described as proactive, considering personal intentions and the need for governance structure improvement, aligning with new legal requirements [2]. Group 2: Performance and Strategic Investments - The company acknowledges that short-term performance pressures are a result of a "growing pains" phase during its transformation, reflecting significant strategic investments in high-barrier products [3][4]. - Lino Pharmaceutical is focusing on high-tech pharmaceutical packaging, particularly in innovative products like borosilicate molded bottles and pre-filled syringes, which are essential for enhancing core competitiveness and long-term positioning [3][4]. Group 3: Long-term Vision and Shareholder Dynamics - The company is committed to bearing the costs of transformation, including increased investments in market expansion, R&D, and talent acquisition, viewing these as necessary for future growth despite short-term profit pressures [4]. - The recent shareholder reductions are attributed to normal market behavior related to fund cycles and employee stock plans, with the core management team not participating in the reductions, indicating a strong alignment of interests between management and the company's long-term goals [4][5].

Management Changes - The recent management changes at Shandong Linuo Pharmaceutical Packaging Co., Ltd. are primarily based on personal willingness, optimization of job functions, and improvement of governance structure [1] - The former chairman Yang Zhongchen resigned due to reaching the legal retirement age, and was succeeded by Song Lai, the former director and deputy general manager [1] - The company has canceled the supervisory board to strengthen governance and internal supervision, with former supervisors and employee representatives transitioning to directors [1] Performance Fluctuations - The company acknowledges that it is currently experiencing a "growing pain" period during its transformation and upgrade, which is driven by forward-looking strategic investments [2] - The strategic focus has shifted towards the high-barrier pharmaceutical packaging sector, with increased capital investment in products like borosilicate molded bottles and pre-filled syringes [2] - The long certification cycle in the pharmaceutical packaging industry means that the benefits of new production capacity will take time to materialize, but profitability is expected to recover as capacity is gradually released [2] Shareholder Reductions - The reduction in shareholding by the Fosun Group is attributed to the fund's lifecycle and redemption pressures, which is considered a normal market exit [2] - The employee stock ownership platform's reduction is due to exceeding a ten-year duration, aimed at meeting the financial needs of current, former, and retired employees [2] - The core management team did not participate in the share reduction, indicating confidence in the long-term development of the company [2] Overall Strategy - The company is undergoing a systematic and deep transformation, focusing on governance optimization, strategic emphasis on high-end products, continuous R&D investment, and bearing transformation costs [3] - Management expresses confidence that as the market stabilizes and new capacities and businesses mature, the company is expected to achieve higher quality and more sustainable development [3]

Group 1 - The company has undergone management adjustments, including the resignation of the former chairman and other board members, to align with new legal requirements and improve governance structure [1][2] - The management changes are seen as proactive adjustments to enhance governance and internal supervision, with experienced personnel being appointed to the board [1][3] - The company is focusing on high-tech pharmaceutical packaging solutions, indicating a strategic shift towards higher value-added products [2][3] Group 2 - The company is currently experiencing a "growing pain" period during its transformation, with a clear strategic focus on high-tech pharmaceutical packaging, which requires significant capital investment [2][3] - Despite short-term financial pressures, the company continues to invest in R&D and talent acquisition to maintain technological leadership and future growth potential [2][3] - Shareholder reductions are explained as normal market behavior, with specific reasons related to fund lifecycle and employee stock plan considerations [3][4] Group 3 - The company is expected to overcome short-term development bottlenecks and enhance profitability and market competitiveness as the market stabilizes and new capacities come online [4]

Group 1 - The core management team of Linuo Pharmaceutical has undergone significant changes, with nearly half of the key management replaced in the last three months [1] - Cao Zhongyong, the former deputy general manager, has resigned but will continue to work in the company, focusing on human resources and overseas business development [1] - Song Lai has taken over as the legal representative and chairman of the company, succeeding Yang Zhongchen, who retired [1] Group 2 - The actual controller of Linuo Pharmaceutical, Gao Yuankun, has joined the board as a non-independent director, indicating a potential shift in strategic direction from the controlling shareholder [1] - The company was listed on the ChiNext board in November 2021, focusing on the research, production, and sales of borosilicate glass, with key products including medicinal glass and heat-resistant glass [1] - In the third quarter report, heat-resistant glass accounted for 57.02% of the main business revenue, while medicinal glass made up 40.74% [1] Group 3 - In 2022, the company's performance declined, with revenue decreasing by 7.52% and net profit dropping by 6.51% [2] - In 2023, the net profit saw a significant decline of 43.49%, following a slight increase of 0.23% in the previous year [2]

（文章来源：证券日报） 证券日报网讯 12月25日，力诺药包发布公告称，山东力诺医药包装股份有限公司于近日收到股东济南 鸿道新能源合伙企业（有限合伙）（以下简称"鸿道新能源"）出具的《关于减持山东力诺医药包装股份 有限公司股份触及1%整数倍的告知函》，鸿道新能源于2025年12月18日至2025年12月24日以集中竞价 交易方式累计减持公司股份1，671，000股，占公司总股本的0.7234%（公司总股本以剔除公司回购股 份后的股份数量230，985，190股为计算依据，下同）。截至2025年12月24日，鸿道新能源按减持计划 减持力诺药包股份触及1%整数倍。 ...